Literature DB >> 28975854

Clinical application of intra-aortic balloon counterpulsation in high-risk patients undergoing cardiac surgery.

Dengbang Hou1, Feng Yang1, Xiaotong Hou1.   

Abstract

The intra-aortic balloon pump (IABP) has been the most commonly used mechanical circulatory support device for nearly five decades. In theory, the IABP can increase the blood and oxygen supply of the coronary artery by increasing the diastolic pressure in the aortic root when the balloon is inflated and reduce left ventricular afterload by rapidly deflating the balloon during the systolic phase. Therefore, some researchers put forward the idea of preoperative prophylactic use of an IABP, which has been frequently performed in high-risk patients undergoing elective percutaneous coronary intervention (PCI) or coronary artery bypass graft surgery (CABG). Previous studies have suggested preoperative IABP has a controversial effect on patients undergoing revascularization; the role of preoperative IABP insertion in those patients undergoing CABG alone remains uncertain. This review will give further insight into routine IABP use by presenting the basic principles and discussing current evidence.

Entities:  

Keywords:  IABP; cardiac surgery; low cardiac output syndrome; mortality

Mesh:

Year:  2017        PMID: 28975854     DOI: 10.1177/0267659117734630

Source DB:  PubMed          Journal:  Perfusion        ISSN: 0267-6591            Impact factor:   1.972


  2 in total

1.  Intensive care outcome of left main stem disease surgery: A single center three years' experience.

Authors:  Amr S Omar; Samy Hanoura; Yasser Shouman; Praveen C Sivadasan; Suraj Sudarsanan; Hany Osman; Abdul Rasheed Pattath; Rajvir Singh; Abdulaziz AlKhulaifi
Journal:  World J Crit Care Med       Date:  2021-01-09

2.  Intraoperative intra-aortic balloon pump improves 30-day outcomes of patients undergoing extensive coronary endarterectomy.

Authors:  Zhen Wu; Changcheng Liu; Ying Fang; Hua Wei; Chengxiong Gu
Journal:  J Cardiothorac Surg       Date:  2020-08-20       Impact factor: 1.637

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.